Siteman Cancer Center is among the first to offer a newly approved cell-based immunotherapy targeting melanoma, approved by the FDA. Washington University physicians at the center will administer TIL therapy to treat certain patients with metastatic melanoma that has not responded to other treatments. This therapy, developed by Iovance Therapeutics, uses the patient’s own T cells to target and kill cancer cells. Results from clinical trials showed promising outcomes, with some patients experiencing tumor shrinkage and remission. The therapy involves chemotherapy to prepare the body for the new T cells, which can cause various side effects that are manageable but sometimes severe.
Source link
New cell-based immunotherapy offered for melanoma
